Mirador Therapeutics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $1.6B
Overview
A precision immunology company using human genetics to discover new drug targets.
ImmunologyRespiratoryDermatology
Technology Platform
Utilizes a human genetics-driven platform integrating computational biology and translational science to identify and validate novel immunology targets.
Funding History
4Total raised:$1.6B
Series D$400M
Series C$400M
Series B$400M
Series A$400M
Opportunities
The approach de-risks drug development by focusing on targets with strong human genetic validation, potentially leading to higher success rates.
Risk Factors
Early-stage company risk; its novel genetic targets may not yield druggable molecules or demonstrate efficacy in clinical trials.
Competitive Landscape
Enters a crowded immunology field where many companies are also leveraging genetic data, requiring novel target discovery to stand out.